N/A
N=60
Medtronic Closed-Loop Spinal Cord Stimulation System
Low Back Pain · Leg Pain · Upper Limb Pain
Bottom Line
View on ClinicalTrials.gov: NCT05177354 ↗Enrolled (actual)
60
Serious AEs
16.7%
Results posted
Oct 2024
Primary outcome: Primary: Reduction in Overstimulation Sensation — 25 Participants — p=<0.001
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Inceptiv (Device)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- MedtronicNeuro
- Primary completion
- May 2023
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Reduction in Overstimulation Sensation |
25 | <0.001 sig |
| SECONDARY Responder Rate for Treatment of Overall Pain |
44 | — |
| SECONDARY Responder Rate for Treatment of Low-back Pain |
38 | — |
| SECONDARY Responder Rate for Treatment of Leg Pain |
30 | — |
Summary
The purpose of the study is to further understand the closed-loop feature in chronically implanted patients by characterizing the efficacy of the next generation, spinal cord stimulator.
Eligibility Criteria
Inclusion Criteria
- 18 years of age or older
- Candidate is undergoing Medtronic SCS device trial for chronic, intractable pain of the trunk and/or limbs
- If being treated for low-back and/or leg pain,
- the baseline overall^ Visual Analog Scale is ≥ 60 mm and
- baseline back and/or leg pain Visual Analog Scale is ≥60 mm. ^Average overall pain in the back and/or leg in the 72 hours prior to the baseline visit, measured using Visual Analog Scale.
- If being treated for upper limb pain - baseline Visual Analog Scale is ≥ 60 mm for upper limb pain
- On stable (no change in dose, route, or frequency) prescribed pain medications being used for back and leg pain or upper limb pain, as determined by the investigator, for at least 28 days prior to device trial
- Willing and able to provide signed and dated informed consent
- Willing and able to comply with all study procedures and visits
Exclusion Criteria
- Indicated for an SCS device to treat stable intractable Angina Pectoris or Peripheral Vascular Disease of Fontaine Stage III or higher
- Previously trialed or implanted with spinal cord stimulator, peripheral or vagus nerve stimulator, deep brain stimulator or an implantable intrathecal drug delivery system
- Currently participating, or plans to participate, in another investigational study unless written approval is provided by the Medtronic study team
- Major psychiatric comorbidity or other progressive diseases that may confound study results, as determined by the Investigator
- Serious drug-related behavioral issues (e.g. alcohol dependency, illegal substance abuse), as determined by the Investigator
- Pregnant or planning on becoming pregnant (if female and sexually active, subject must be using a reliable form of birth control, be surgically sterile, or be at least 2 years post-menopausal)
- Be involved in an injury claim or under current litigation
Data sourced from ClinicalTrials.gov (NCT05177354). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.